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Introduction
　The ryanodine receptor （RyR） is a family of Ca2＋ release channels located in the mem-
brane of intracellular Ca2＋ storage organelles.  Three mammalian RyR isoforms encoded 
by distinct genes have been cloned and fully sequenced ; all are approximately 5000 amino 
acids long with a molecular weight of more than 550 kDa.  Each monomeric RyR isoform 
can homotetramerize to form its respective functional Ca2＋ release channel 1）.
　The type 1 RyR isoform （RyR1） is known as the skeletal-type RyR based on the initial 
purication and cDNA cloning from skeletal muscle 2）.  RyR1 is also expressed in the brain, 
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although in much smaller amounts than found in striated muscle 3, 4）.  Takashima et al 5） 
reported the rst evidence for a brain-specic transcript of RyR1, as an RNA transcript of 
approximately 2400 nucleotides that encoded only 656 amino acids.  This represents a trun-
cated version of RyR1 that would begin just before 4382methionine and extend to 5037serine 
of the full-length RyR1 protein.  This protein is sorted into the membrane of endoplasmic 
reticulum （ER）-located intracellular Ca2＋ storage sites in Chinese hamster ovary （CHO） 
cells transfected to express only this 3’-terminal portion of RyR1 cDNA.  However, pharma-
cological experiments with these transformed CHO cells showed no Ca2＋ release in response 
to caffeine, a representative RyR1-stimulating drug that induces a signicant rise in intracel-
lular Ca2＋ concentration in CHO cells expressing full-length RyR15, 6）.  Substantial questions 
remain regarding the functional signicance of brain cells expressing both the short and full-
length forms of RyR1.
　This study therefore investigated possible roles of the brain-specific transcript of RyR1 
in regulating intracellular Ca2＋ signals with and without coexpressed full-length RyR1.  We 
have established an experimental system for coexpressing both forms of RyR1 in brain that 
involves gene transfer of the brain-specic short form of RyR1cDNA to stable cell lines 
induced to express the full-length RyR1 protein.
Materials and Methods
　The transfection efciency in cells depends on the size of the target DNA, and the full-
length RyR1 cDNA （about 16,000 bp） was too long to be coexpressed quantitatively with 
the shorter cDNA of the brain-specic RyR1 transcript （～ 2,400 bp） transfected into the 
same cells.  We therefore established the following methods to coexpress the two RyR1 
cDNAs.
Establishment of stable cell line induced to express full-length RyR1
　The Flp-InTM T-RExTM System （Invitrogen, Carlsbad, CA） used here 7） was modied to 
establish stable cell lines expressing full-length RyR1.  In brief, the Flp-In T-REx293 cells 
（Invitrogen） were cultured in Dulbecco’s modied Eagle’s medium （Wako Pure Chemicals 
Industries, Osaka, Japan） containing 10% fetal bovine serum and 100 U/ml of penicillin, and 
100μg/ml of streptomycin （Wako Pure Chemicals Industries）.  The tetracycline-inducible 
expression vector pcDNA5/FRT/TO （Invitrogen） was modied by the addition of an NheI 
site in its multicloning sites to insert full-length RyR1 cDNA 8） digested by XbaI/EcoRV 
between the NheI and the EcoRV sites.  Cotransfection of the expression vector containing 
full-length RyR1cDNA and the pOG44 vector encoding Flp recombinase （Invitrogen） was 
carried out by the calcium phosphate precipitation method using a Profection Mammalian 
Transfection System Kit （Promega, Madison, WI）.  Transfected cells were washed at 4 h 
after the transfection and allowed to grow in fresh medium for a further 2 days.  The medi-
um was replaced with the same growth medium containing 200μg/ml hygromycin B （Wako 
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Pure Chemicals Industries） to select transformed cells.  This selection medium was changed 
every 3-4 days until the desired cell number was reached.  Doxycycline, a stable tetracycline 
derivative, （Dox ; 1μ g/ml, Sigma -Aldrich Co, St. Louis, MO） was added to the selected 
cells for 48-72 h to induce the expression of full-length RyR1 protein.  Immunocytochemical 
staining with polyclonal antibodies against the D2 region （amino acid 1358-1413） of rabbit 
RyR1 was carried out as previously described 9） to confirm the expression of exogenous 
RyR1 in the cells.
Coexpression of the brain-specic splice variant of RyR1 in the full-length RyR1-expressing cells
　The domain corresponding to the brain-specic transcript of RyR15）, which is approxi-
mately 2.4 kb of the 3’-terminal of the full-length RyR1 cDNA （about 15 kb）, was amplied 
by using the high delity KOD Plus polymerase （TOYOBO, Osaka, Japan）.  PCR to make 
products tagged at the C-terminus with enhanced green fluorescent protein （GFP） was 
performed on the full-length RyR1cDNA template fused with the amino-terminal of GFP 
in pBluescript KS （＋） as previously reported 10）, with the following primer pairs （restriction 
enzyme recognition sites are underlined）, XhoI-4382Met-F （5’-CCGCTCGAGGGATGC-
CCGATCCCACCAGCGACGAGG-3’） and T3 （5’-AATTAACCCTCACTAAAGGG-3’）. 
Another set of primers for making the PCR product fused with the C-terminal of GFP was 
as follows : the RyR1C （＋KOZAC）-F （5’-GCGGCTAGCGCCGCCACCATGGCCGATC-
CCACCAGCGACGAGGTGCACGG-3’）/RyR1C （EcoRV）-R （5’-CAAGCTTGATATC-
GAATTCCTGCAGCCCGGGGG-3’）; restriction enzyme recognition sites are underlined 
and the Kozac initiation sequence 11） for translation is shown in italics）.  The PCR products 
were ligated into the GFP expression vectors 12） after double digestion of the PCR products 
with restriction enzymes XhoI/HindIII for the former PCR product or NheI/EcoRV for the 
latter product.  DNA sequencing was performed by Macrogen Japan （Tokyo, Japan） to vali-
date the nucleotide sequence encoding the brain-specic RyR1 transcript.  These GFP-tagged 
expression vectors were transfected into the Flp-In T-REx293 cells （Invitrogen） by the same 
procedure as described.
　To coexpress the GFP-tagged brain-specic form of RyR1 with the full-length RyR1 in 
the same cells, each GFP expression vector was introduced into the previously established 
HEK293 cells Dox-induced to express full-length RyR1 according to the calcium phosphate 
precipitation methods of the same kit （Promega）.
SDS-polyacrylamide gel electrophoresis （PAGE） and western blotting
　SDS-PAGE was performed on 2-12% linear gradient gels with standard proteins at （in 
kDa） 205 （myosin heavy chain）, 116 （b-galactosidase）, 97.4 （phosphorylase b）, 66 （bovine 
serum albumin）, and 45 （ovalbumin）.  Gels were stained with Coomassie Brilliant Blue and 
the separated proteins were electrophoretically transferred overnight onto PVDF membranes 
in the presence 0.02% SDS.  Immunodetection was carried out with an ECL system （GE 
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Healthcare UK, Ltd., Little Chalfont, Buckinghamshire, England） using primary antibodies 
against the D2 region of RyR1 and peroxidase-conjugated secondary antibodies.
Imaging of intracellular Ca2＋ concentration
　Changes in intracellular Ca2＋ levels of cultured cells were measured using the Ca2＋ 
indicator dye Fura-2.  Cells were loaded with 4μM Fura-2/AM （Molecular Probes, Eugene, 
OR） in a physiological salt solution （150 mM NaCl, 4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 
5.6 mM glucose, 5 mM HEPES, adjusted to pH 7.4 with NaOH） containing 0.1% bovine 
serum albumin V （Sigma-Aldrich） for 30 minutes at room temperature.  Cells were viewed 
under an inverted uorescence microscope （IX70, Olympus, Tokyo, Japan） equipped with a 
charge-coupled device camera （Rolera, QImaging, Burnaby, Canada）.  Changes in the intrac-
ellular Ca2＋ concentration were measured by monitoring the ratio of the uorescence signals 
at 515-550 nm with alternate excitations at 345 and 380 nm.  Image analysis was performed 
using IPLab software （Signal Analytics, Glen Allen, VA）.  Images were converted to 345/380 
ratio images by ImageJ software （National Institutes of Health, Bethesda, MD） and then 
averaged over the whole area sampled.  Images were captured by a high-sensitivity charge-
coupled device digital camera （DP70, Olympus） using image-capture software （DP Control, 
Olympus）, and analyzed using ImageJ.  Changes in the ratios of the uorescence intensity at 
345 nm to that at 380 nm were normalized to the average resting value before the rst drug 
application.
Reagents
　Caffeine was purchased from Wako Pure Chemicals Industries. 
Data analysis
　All results from the normalized values of the uorescence ratios are expressed as mean ± 
SEM.  Statistical differences between groups were evaluated by unpaired t-tests.  A P value 
of 0.0005 or less was considered to indicate a signicant difference between groups.
Results
　Prior to applying the Flp-In T-REx system, we performed a trial with a simple method to 
express two different genes transiently using a single expression vector such as the pIRES 
（internal ribosome entry site） bicistronic expression vector （Clontech Laboratories, Mountain 
View, CA） or pBI （bidirectional） expression vector （Clontech）13）.  However, the nal size 
of these expression vectors （＞250,000 bp） was too large for the efcient expression of both 
recombinant proteins.  Therefore, we instead established stable cell lines expressing full-length 
RyR1 encoded by the larger vectors, and then transiently expressed the brain-specic form 
of RyR1 in the stably expressing cells by standard transfection procedures.
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Establishment of stable HEK293 cell lines induced to express full-length RyR1
　Using the Flp-In T-REx system, we established a stable cell line of HEK293 cells Dox-
inducibly expressing the full-length RyR1.  This system allowed integration of the full-
length cDNA of RyR1 in mammalian cells at a specific integrated FRT site in the 
genome.  SDS-PAGE and Western blotting of cell lysates from multiple stable clones 
selected by hygromycin B resistance （Fig. 1A） revealed the expression of full-length RyR1 
to approximately the same level in all six clones （Fig. 1B）.  Immunocytochemical analysis 
conrmed the similar efciencies of RyR1 expression across the stable cell lines （Fig 1C）, 
showing much stronger uorescent signal in the cytoplasm than in the nucleus, as previously 
reported 12-14）.  These results indicated highly reproducible expression of exogenous RyR1 
at the expected location from cell to cell and from clone to clone using this experimental 
system.
Expression of the brain-specic transcript of RyR1 in HEK293 cells
　We constructed the truncated form of RyR1cDNA corresponding to the brain-specific 
transcript of RyR1 to be expressed as a GFP-fusion protein.  Stable cell lines inducibly 
expressing the brain-specific form of RyR1 were also established by the Flp-In T-Rex 
system.  GFP-fluorescence was observed for both clones inducibly expressing the short 
forms tagged by GFP at its N- or C- terminus respectively, although the signal intensity 
was slightly stronger with the GFP at the C-terminal of RyR1 compared to tagging at the 
N-terminus （Fig. 2A and 2C）.  The intracellular distribution of the GFP-fusion proteins was 
predominantly cytoplasmic （Fig. 2A and 2C）, as described previously with full-length RyR1-
GFP fusions 12, 14）.  These results suggested that both of the GFP-tagged brain-specic RyR1s 
were expressed appropriately at intracellular Ca2＋ store sites such as endoplasmic reticulum 
where intracellular Ca2＋ release channels are located to transduce intracellular Ca2＋ 
signaling 15）.
Coexpression of the brain-specic transcript of RyR1 with full-length RyR1 in HEK293 cells
　We introduced the expression vectors encoding the brain-specific short form of 
RyR1cDNA into the cells expressing full-length RyR1 in the presence of Dox by the 
calcium phosphate precipitation method.  Some cells in the culture dishes emitted GFP-
fluorescence （GFP-positive） indicating expression of the brain-specific form of RyR1, 
while other cells expressing full-length RyR1 alone showed no GFP-fluorescence （GFP-
negative）.  Approximately 48 hours after the gene-transfer, we compared the functional 
properties of the Ca2＋ release channels of the GFP-positive cells with those of the GFP-
negative cells in the same dishes by applications of caffeine as an agonist of the Ca2＋ 
release function of RyR1.  All cells showed dose-dependent increases in intracellular Ca2＋ 
concentration measured uorimetrically （345/380 ratio） obtained using 345 nm and 380 nm of 
excitation light under a uorescence microscope.  However, the caffeine-induced increases in 
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intracellular Ca2＋ concentration were signicantly decreased in GFP-positive cells compared 
to GFP-negative cells, while the same Ca2＋ concentrations were observed in both types of 
cells under resting conditions without caffeine （Fig. 3A and 3B）.  The inhibitory effects 
observed in GFP-positive cells were decreased in a dose-dependent manner to the higher 
Fig. 1.   Establishment of stable HEK293 cell lines induced to express full-length 
RyR1
（A） SDS-PAGE and Western blotting of whole cell extracts from the 
hygromycin B-selected HEK293 cells as the stable cell line induced to express 
full-length RyR1.  Size markers （M） and 30 μg of the whole cell extract were 
subjected SDS-PAGE on a gradient gel and stained with Coomassie Brilliant 
Blue （CBB）（left）.  Similar gels were transferred onto PVDF membrane and 
probed with anti-D2 of RyR1 polyclonal antibodies （right）.  （B） Quantitative 
comparison of expressed RyR1 from six independent stable cell lines.  Western 
blotting was performed in each cell extract from six clones of the stable 
cell lines induced to express RyR1 with the anti-D2 of RyR1 antibodies. 
（C） Expression and distribution of exogenous RyR1 in HEK293 cells. 
Immunocytochemical staining of the expressed RyR1 in individual cells was 
performed with anti-D2 of RyR1 polyclonal antibodies and TRITC-conjugated 
secondary antibodies.  The TRITC-red uorescent images from the Dox-induced 
HEK293 cells expressing RyR1 are shown in the left panel （F） and the phase 
contrast images of the same eld are shown in the right panel （P）.
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concentration of caffeine.  Moreover, the suppressive activities of the brain-specic form of 
RyR1 were stronger in cells expressing the GFP tagged at the N-terminal of RyR1 than in 
cells expressing the C-terminal tagged protein （Fig. 4A and 4B）.
Discussion
　In this study, we developed an experimental system for coexpressing two genes that differ 
by approximately 10-fold in length in the same cells.  We showed the novel nding that 
coexpression of the brain-specic transcript of RyR1 and full-length RyR1 in the same cell 
altered the sensitivity of Ca2＋ release channels in that cell.
　Molecular cloning and hydropathy plot analysis of predicted amino acid sequences （about 
5000 amino acids as the full length） indicated that a large hydrophilic N-terminal ‘foot’ 
region and smaller hydrophobic C-terminal （10-20% of the protein ; last 500-1000 amino 
acids） region containing putative 4 to 10 transmembrane segments form the conduction 
pore of a Ca2＋ release channel 2, 16）.  Heterologous expression of the truncated RyR1 
demonstrated that the C-terminal 1030 amino acids could function as an ion channel in 
planar lipid bilayers 17, 18）.  Recently, gel ltration analysis of puried C-terminal regions of 
Fig. 2.   Expression and distribution of the exogenous brain-specific form of 
RyR1 in HEK293 cells
Fluorescence images of HEK293 cells expressing the GFP-tagged brain-specic 
form of RyR1 fused at the N-terminus of RyR1 （A） or at the C-terminus （C）. 
The corresponding phase-contrast images of the same elds of （A） and （C） 
are shown in （B） and （D）, respectively.
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the RyR1 protein showed that the last 209 19） or 100 amino acids 20） were capable of self-
tetramerization as structurally required for the functional ion channel.  Therefore, it is 
possible that the brain-specic transcript of RyR1 （last 656 amino acids） is incorporated into 
the assembly of RyR1 Ca2＋ release channels as a dominant-negative regulator.
　GFP-tagging at either end of the brain-specic RyR1 produced slightly different inhibitory 
effects on the caffeine-induced Ca2＋ release in cells coexpressing full-length RyR1.  Protein-
Fig. 3.   Effects of Coexpression of the brain-specific form of RyR1 on 
caffeine-induced intracellular Ca2＋ mobilization in HEK293 cells 
expressing full-length RyR1
Time courses of intracellular Ca2＋ concentration changes in the transfected 
HEK293 cells coexpressing full-length RyR1 and the brain-specic form tagged 
by GFP at the N-terminus （A） or at the C-terminus （B）.  The closed- and 
open- symbols are from the GFP-positive or GFP-negative cells, respectively. 
Applications of caffeine are shown in the gray bars at the concentrations 
indicated （mM）.  The vertical scale shows the fluorescence ratio of fura2 
intensities （as described in Materials and Methods） and the horizontal scale 
shows the timeline （sec）.  Values are expressed as the mean ± SEM.
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protein interaction analyses have shown that removing the nal 15 amino acids from the 
C-terminus of RyR1 eliminates the capacity for oligomeric association 21）.  Moreover, GFP 
fusion to the C-terminal end of the full-length protein completely abrogates the caffeine-
induced Ca2＋ release activity 10, 22）.  These results indicated that slight conformational changes 
to RyR1 could influence the incorporation of the dominant-negative subunit （truncated 
RyR1） into the tetramer.
　Malignant hyperthermia （MH） is an autosomal dominant pharmacogenetic disorder 
of skeletal muscle, triggered in predisposed individuals by inhalation of anesthetics （e.g. 
halothane） or by depolarizing muscle relaxants （e.g. succinylcholine）23）.  More than 80 
different mutations in the RyR1 gene have been found in patients with MH and/or its 
related congenical myopathy of central core disease （CCD）, which is characterized by 
large amorphous areas （cores） that lack mitochondria or oxidative enzyme activity and 
hypotonia during infancy, proximal muscle weakness, delayed motor development, and 
reduced muscle bulk.  Although the reported RyR1 mutations cluster in three separate 
regions ［the N-terminus, the central domain, and the C-terminus containing the channel 
pore 23, 24）］, MH-linked mutations are mostly found in the N-terminal and central regions. 
The MH-related amino acid substitutions in RyR1 exogenously expressed in cultured cells 
enhances the caffeine or halothane sensitivities of the Ca2＋ release channel activities, which 
has also been reported in muscle biopsies from MH patients 8, 13）.  The brain-specic short 
form of RyR1 might therefore confer local protective effects on the MH symptoms by 
blocking the function of the MH-related regions of full-length RyR1.
Fig. 4.   Inhibitory effect of Coexpression of the brain-specic form of RyR1 with full-length 
RyR1 on caffeine-induced Ca2＋-releasing activities in HEK293 cells
Each column shows the peak level （mean ± SEM, n = 7-46） of intracellular Ca2＋ response 
induced by caffeine at the concentration indicated （mM）.  ＊P < 0.0005 versus HEK293 
cells expressing the full-length of RyR1 alone （white columns） that did not show any GFP 
uorescence in the cytosol.
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　RyR genes contain more than 100 exons, and many tissue-specific or developmentally 
regulated splice variants have been reported 25-27）.  One such variant that is overexpressed 
in adult myotonic dystrophy type 1 was recently implicated to be of pathophysiological 
signicance 28）, although the physiological roles of RyR1 variants largely remain unknown. 
Further studies into the roles of RyR1 splice variants should provide important insight into 
not only universal intracellular Ca2＋ signaling but also the tissue-specic regulation of Ca2＋ 
signaling in specic tissues including brain and muscle 29）.
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